Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Science for Life, Utrecht University, 3508 TB Utrecht, The Netherlands.
Regenerative Medicine Centre, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands; Centre for Molecular Medicine, University Medical Centre Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands; Biomedical Primate Research Centre, 2288 GJ Rijswijk, The Netherlands.
J Control Release. 2023 Mar;355:685-708. doi: 10.1016/j.jconrel.2023.01.060. Epub 2023 Feb 18.
Extracellular vesicles (EVs) are a population of small vesicles secreted by essentially all cell types, containing a wide variety of biological macromolecules. Due to their intrinsic capabilities for efficient intercellular communication, they are involved in various aspects of cellular functioning. In the past decade, EVs derived from stem cells attracted interest in the field of regenerative medicine. Owing to their regenerative properties, they have great potential for use in tissue repair, in particular for tissues with limited regenerative capabilities such as cartilage. The maintenance of articular cartilage is dependent on a precarious balance of many different components that can be disrupted by the onset of prevalent rheumatic diseases. However, while cartilage is a tissue with strong mechanical properties that can withstand movement and heavy loads for years, it is virtually incapable of repairing itself after damage has occurred. Stem cell-derived EVs (SC-EVs) transport regenerative components such as proteins and nucleic acids from their parental cells to recipient cells, thereby promoting cartilage healing. Many possible pathways through which SC-EVs execute their regenerative function have been reported, but likely there are still numerous other pathways that are still unknown. This review discusses various preclinical studies investigating intra-articular injections of free SC-EVs, which, while often promoting chondrogenesis and cartilage repair in vivo, showed a recurring limitation of the need for multiple administrations to achieve sufficient tissue regeneration. Potentially, this drawback can be overcome by making use of an EV delivery platform that is capable of sustainably releasing EVs over time. With their remarkable versatility and favourable chemical, biological and mechanical properties, hydrogels can facilitate this release profile by encapsulating EVs in their porous structure. Ideally, the optimal delivery platform can be formed in-situ, by means of an injectable hydrogel that can be administered directly into the affected joint. Relevant research fulfilling these criteria is discussed in detail, including the steps that still need to be taken before injectable hydrogels for sustained delivery of EVs can be applied in the context of cartilage regeneration in the clinic.
细胞外囊泡 (EVs) 是一种由几乎所有细胞类型分泌的小囊泡群体,其中包含多种生物大分子。由于其具有高效细胞间通讯的固有能力,因此它们参与了细胞功能的各个方面。在过去的十年中,源自干细胞的 EVs 引起了再生医学领域的关注。由于其再生特性,它们在组织修复中具有很大的应用潜力,特别是在软骨等再生能力有限的组织中。关节软骨的维持依赖于许多不同成分的微妙平衡,而这些成分可能会被常见的风湿性疾病所破坏。然而,尽管软骨是一种具有强大机械性能的组织,可以承受多年的运动和重负荷,但在受到损伤后几乎无法自我修复。源自干细胞的 EVs (SC-EVs) 将再生成分(如蛋白质和核酸)从其亲本细胞运送到受体细胞,从而促进软骨愈合。已经报道了许多 SC-EVs 执行其再生功能的可能途径,但可能还有许多其他途径仍然未知。本综述讨论了各种研究关节内注射游离 SC-EVs 的临床前研究,尽管这些研究通常在体内促进软骨形成和软骨修复,但存在需要多次给药才能实现足够组织再生的反复限制。通过利用能够随着时间的推移持续释放 EVs 的 EV 传递平台,可能可以克服这一缺陷。水凝胶具有出色的多功能性和有利的化学、生物和机械特性,可以通过将 EVs 包封在其多孔结构中来促进这种释放特性。理想情况下,可以通过注射可注入的水凝胶原位形成最佳的传递平台,该水凝胶可以直接施用于受影响的关节。详细讨论了满足这些标准的相关研究,包括在将用于持续释放 EVs 的可注射水凝胶应用于临床软骨再生之前还需要采取的步骤。